Down 7.7% today, more than its biotech peers' 2.4%; no story names it yet.
Down 11% since Oct 7
Down 11% from Oct 7 to Oct 30 while the S&P 500 fell 3%.
SMMT's Quality Score fell 1 point on Mon, Nov 2, to -3. Trading picked back up.
Follow SMMT's trial news. Pro members can get an alert when Summit Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Long-term trend | −3 |
| Latest filing | 8-K, Sep 29 |
TodayNo story names it yet.
Wed Nov 4: Special meeting, online11:00 AM ET. Proxy filed Oct 19.
After its last 4 reports it closed -11.7% on average, higher 1 of 4 times.
About 6 quarters
No shelf registration or at-the-market program on file in the last three years.
CEO Mahkam Zanganeh bought 3,810,000 shares on Jun 12. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
SMMT is #172 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 172 |
Cash and short-term investments: SMMT $691M, ELVN $895M, SLS $138M, EWTX $72.3M.
Expected to report Tue Nov 3, after the close (tomorrow). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease in GAAP operating expenses was due to the decrease in stock-based compensation expense of $410.1 million primarily related to the modification to the company’s performance-based stock option awards during the second quarter of 2025.”
SMMT's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
No outlook figures read from this release.
“The increase in Non-GAAP operating expenses was primarily driven by the expansion of clinical studies and development costs related to ivonescimab.”
From its results filing (SEC filing · Jul 23)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Jul 23, 2026 | -8.4% | -8.8% | -10.3% |
| Apr 30, 2026 | -25.4% | -24.9% | -20.1% |
| Feb 23, 2026 | -1.9% | +0.2% | +0.6% |
3 insiders bought $104M across 6 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SMMT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
“The markets for oncology pharmaceuticals, in which we compete, are characterized by significant scientific innovation, regulatory oversight and intense competition.”
SMMT scores -3 today, which Breakaway calls Poor. It is #172 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 11% from Oct 7 to Oct 30 while the S&P 500 fell 3%. Cash lasts about 6 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SMMT scores -3 today, which Breakaway calls Poor (below zero). That is #172 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SMMT's -3.
3 insiders bought $104M across 6 filings in the last 6 months. No open-market sales on record. The newest is Mahkam Zanganeh, Co-Chief Executive Officer, who bought $50M on Jun 12. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.